Genmab A/S Stock Nasdaq
Stocks
GMAB
US3723032062
Biotechnology & Medical Research
OTC Markets Traded|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.57 USD | -1.48% |
|
-0.21% | -6.53% |
| Market Cap | 115B 17.45B 15.33B 14.31B 13.13B 24.59B 1,671B 25.19B 170B 66.37B 827B 65.51B 64.09B 2,859B | P/E 2026 * |
24.4x | P/E 2027 * | 16.9x |
|---|---|---|---|---|---|
| Enterprise Value | 134B 20.4B 17.93B 16.73B 15.36B 28.75B 1,954B 29.46B 198B 77.6B 967B 76.6B 74.94B 3,343B | EV / Sales 2026 * |
4.74x | EV / Sales 2027 * | 3.81x |
| Free-Float |
95.41% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Genmab A/S
| 1 day | -1.60% | ||
| 1 week | -0.21% | ||
| Current month | +4.81% | ||
| 1 month | +10.65% | ||
| 3 months | +10.26% | ||
| 6 months | -13.67% | ||
| Current year | -6.53% |
| 1 week | 28.33 | 29.38 | |
| 1 month | 27.33 | 29.8 | |
| Current year | 23.62 | 35.43 | |
| 1 year | 21 | 35.43 | |
| 3 years | 17.24 | 41.58 | |
| 5 years | 17.24 | 49.07 | |
| 10 years | 12.1 | 49.07 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 01/06/2010 | |
Anthony Pagano
DFI | Director of Finance/CFO | 48 | 01/03/2020 |
Rayne Waller
CTO | Chief Tech/Sci/R&D Officer | - | 16/08/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 01/11/2003 | |
| Director/Board Member | 58 | 01/01/2015 | |
| Director/Board Member | 75 | 01/01/2015 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.48% | -0.21% | - | - | 17.86B | ||
| +0.47% | +2.03% | +51.54% | +70.84% | 55.01B | ||
| +2.83% | +0.04% | +38.07% | +82.59% | 54.24B | ||
| +0.77% | +2.52% | -15.55% | -13.53% | 23.38B | ||
| -0.46% | -2.03% | -0.50% | +372.97% | 22.57B | ||
| +2.07% | +1.44% | +23.06% | -9.05% | 20.19B | ||
| -2.14% | -2.72% | +30.26% | +536.72% | 15.5B | ||
| -3.14% | -8.09% | +160.68% | +292.18% | 14.2B | ||
| -2.05% | +1.93% | +51.71% | +184.32% | 14.2B | ||
| +1.89% | +2.08% | +86.42% | +167.33% | 12.42B | ||
| Average | -0.24% | -0.69% | +47.30% | +187.15% | 25.75B | |
| Weighted average by Cap. | +0.41% | -0.99% | +41.21% | +144.40% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 28.25B 4.3B 3.78B 3.53B 3.24B 6.06B 412B 6.21B 41.82B 16.36B 204B 16.14B 15.79B 705B | 33.18B 5.05B 4.44B 4.14B 3.8B 7.12B 484B 7.29B 49.12B 19.21B 239B 18.96B 18.55B 828B |
| Net income | 4.82B 733M 644M 601M 552M 1.03B 70.21B 1.06B 7.13B 2.79B 34.74B 2.75B 2.69B 120B | 7.05B 1.07B 944M 881M 808M 1.51B 103B 1.55B 10.44B 4.08B 50.9B 4.03B 3.94B 176B |
| Net Debt | 19.4B 2.95B 2.6B 2.42B 2.22B 4.16B 283B 4.26B 28.73B 11.23B 140B 11.09B 10.85B 484B | 11.82B 1.8B 1.58B 1.48B 1.35B 2.54B 172B 2.6B 17.5B 6.84B 85.27B 6.75B 6.61B 295B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/07/26 | US$28.55 | -1.55% | 876,552 |
| 28/07/26 | US$29.00 | +0.69% | 2,212,644 |
| 27/07/26 | US$28.80 | -0.24% | 1,526,784 |
| 24/07/26 | US$28.87 | -1.03% | 1,676,219 |
| 23/07/26 | US$29.17 | +1.11% | 1,135,422 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.

Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GMAB Stock
- GMAB Stock
Select your edition
All financial news and data tailored to specific country editions




















